Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study is testing pembrolizumab added to intravesical gemcitabine for BCG-unresponsive non-muscle invasive bladder cancer, with the trial currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING